Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 9/20 | 0.70 |
| ▸ | CNR2 | P34972 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.59 |
| ▸ | MCTS1 | Q9ULC4 | 7/20 | 0.48 |
| ▸ | SLC16A1 | P53985 | 6/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926958 | 0.85 | SLC16A3 (0.78) | SLC16A3MCTS1SLC16A1 | |
| SCHEMBL928596 | 0.84 | SLC16A3 (0.76) | SLC16A3MCTS1SLC16A1 | |
| SCHEMBL928309 | 0.84 | SLC16A3 (0.76) | SLC16A3CNR2ACHECNR1MCTS1 | |
| Bindarit SCHEMBL29387325 | 0.83 | SLC16A3 (1.00) | SLC16A3CNR2ACHECNR1MCTS1 | |
| Bindarit SCHEMBL187885 | 0.83 | SLC16A3 (1.00) | SLC16A3CNR2ACHECNR1MCTS1 | |
| SCHEMBL929883 | 0.83 | SLC16A3 (0.74) | SLC16A3MCTS1SLC16A1 | |
| Bindarit SCHEMBL371677 | 0.82 | SLC16A3 (0.98) | SLC16A3CNR2ACHECNR1MCTS1 | |
| SCHEMBL928508 | 0.77 | SLC16A3 (0.87) | SLC16A3CNR2ACHECNR1MCTS1 | |
| SCHEMBL928717 | 0.77 | SLC16A3 (0.87) | SLC16A3MCTS1SLC16A1 | |
| SCHEMBL3318882 | 0.76 | CNR2 (0.67) | CNR2ACHECNR1PLA2G2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181551-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-06-21 | — | — | EP | disclosed |
| EP-2254869-B1 | NEUE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 UND P40 | ACRAF (IT) | 2017-05-31 | — | — | EP | disclosed |
| US-8835481-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2254869-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009109613-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | SLC16A3 2368/4885CNR2 137/4885ACHE 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.